These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 22176941

  • 1. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S.
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [Abstract] [Full Text] [Related]

  • 2. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC.
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 4. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 6. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 STUDY GROUP.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [Abstract] [Full Text] [Related]

  • 7. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 8. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH.
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 11. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 12. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [Abstract] [Full Text] [Related]

  • 13. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
    Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S.
    J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 15. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC, Fiske K, Lyne A.
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [Abstract] [Full Text] [Related]

  • 16. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD.
    Faraone SV, Glatt SJ.
    J Atten Disord; 2010 Mar; 13(5):532-8. PubMed ID: 19395648
    [Abstract] [Full Text] [Related]

  • 17. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
    Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H.
    J Clin Psychiatry; 2020 Apr 14; 81(3):. PubMed ID: 32297719
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR, Lyne A, Wigal T, McGough JJ.
    J Child Adolesc Psychopharmacol; 2009 Jun 14; 19(3):215-26. PubMed ID: 19519256
    [Abstract] [Full Text] [Related]

  • 20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 14; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.